The genomic study of non -Spanish black veterans with prostate cancer attributes basic knowledge of precision medicine

In the largest clinical genomic study of non -Spanish black men with metastatic prostate cancer to date, researchers from the Moffitt Cancer Center, the University of Pennsylvania, the University of California in Los Angeles and the Veterans (VA) groups (VA).

The study, published in Open the Jama NetworkIt analyzed data from more than 5,000 US veterans with prostate cancer, who underwent a sequence of next generation between 2019 and 2023, found that while non -Spanish black veterans had higher rates DNA trails. Despite these biological differences, the survival effects were comparable to equal access VA.

These results confirm that accuracy oncology can be a powerful tool for achieving fair cancer care. Using genomic tests to guide the treatment option, we can match patients with treatments based on their biology of tumor, not breed. “

Kosj Yamoah, MD, Ph.D., Senior Author and President of the Radiation Oncology Program in Moffitt

Dr. Isla Garraway, MD, Ph.D., Author and Director of Research in the UCLA Health Urology Department, emphasized the importance of the impact of the study, “This research reinforces that we should not let historical inequalities determine the contemporary care.

Their basic findings include:

• Non -Spanish black veterans were significantly more likely to have genomic lesions associated with the benefit of immunotherapy, such as micro -medium volatility.
• Non -Spanish white veterans had higher rates of mutations in DNA repair genes and androgen receptor shafts, which may affect the response to hormonal therapies.
• Changes in tumor repression genes were linked to worse survival in both groups.
• No biomarker was found to be excluded from breed -based tests.

The different study group, consisting of 36% of non -Spanish black veterans, represents a remarkable improvement of integration compared to previous genomic studies. The researchers emphasized the importance of continuing to expand access to next generation sequence tests and ensuring that under -supplemented groups are included in precision research and clinical trials.

“This study shows that when we remove obstacles to care and application of medical accuracy, we can improve the results for all patients,” said Kara Maxwell, MD, Ph.D., Author and Assistant Medical Professor at the University of Pennsylvania.

The study was supported by the National Cancer Institute (P30-CA076292), the Prostate Cancer Foundation (PCF222chal02) and the National Oncology Program VA.